Back

Impact of impaired cardiac function on the progression of chronic kidney disease---role of pharmacomodulation of valsartan

30 August 2016 (10:46 - 10:55)
Organised by:
Congress Presentation Part of: Cardiomyopathy with preserved ejection fraction: Amyloidosis and hypertension Drug therapy ESC Premium Access ESC Congress 2016

About the speaker

Photo
Associate Professor Sarah Chua

Chang Gung Memorial Hospital Kaohsiung, Kaohsiung (Taiwan)

5 More presentations in this session

Presentation thumbnail
Prevalence of cardiomyopathy in patients with familial amyloid neuropathy: a report from the NEURO-TTR Trial
Assistant Professor S. Heitner (South San Francisco, US)
Abstract Slides
Presentation thumbnail
Bortezomib: an effective therapy even in cardiac AL patients previously deemed unsalvageable
Doctor A. Singh (Boston, US)
Abstract Slides
Presentation thumbnail
Higher prevalence of hypertension in the migrant population in Italy: data derived from the 2012 and 2013 world kidney day
Associate Professor S. Perlini (Pavia, IT)
Abstract Slides
Presentation thumbnail
Impact of patients' wealth categories on antihypertensive drugs intake in 12 sub-saharan countries: EIGHT Study
Doctor M. Antignac (Paris, FR)
Abstract Slides
Presentation thumbnail
Titration of telmisartan, but not addition of amlodipine, reduces urine albumin in hypertensive patients with diabetes treated with telmisartan plus diuretic
Professor Y. Dohi (Nagoya, JP)
Abstract

Access the full session

Session thumbnail
Cardiomyopathy with preserved ejection fraction: Amyloidosis and hypertension

The Event

Event poster

ESC Congress 2016

30 August 2016 10:46 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources